DOI: 10.1007/s00344-008-9075-2 11
Agin A, Jeandidier N, Gasser F, Grucker D, Sapin R (2006) Use of insulin immunoassays in clinical studies involving rapid-acting insulin analogues: Bi-insulin IRMA preliminary assessment
Evaluating Clinical Fit: Who Benefits From Self-Pay GLP-1 Access Uninsured GLP-1 candidates typically include adults with BMI 25+ and metabolic risk factors (elevated fasting glucose, family history of diabetes, weight-related comorbidities), those seeking preventive metabolic optimization, or patients with documented medication resistance to conventional weight management
The magnitude of decrease in K-18 observed with retatrutide 8 mg and 12 mg has been associated with greater odds of histological improvement in previous studies of patients with MASH 33
This highlights the need for future research that emphasises FFM preservation while promoting fat loss to better elucidate the relationship between FFM and appetite-related hormones